Adjuvant systemic therapy in breast cancer Book Section
| Authors: | Goldfarb, S.; Zhi, W. I. |
| Editors: | Urban, C.; Rietjens, M.; El-Tamer, M.; Sacchini, V. S. |
| Article/Chapter Title: | Adjuvant systemic therapy in breast cancer |
| Abstract: | Patients with early-stage breast cancer are treated with curative intent. The goal of adjuvant therapy is to improve overall survival [1, 2]. After surgery, although there is no evidence of gross remaining disease, patients still have a risk of relapse from occult micrometastatic disease. The goal of adjuvant systemic therapy is to decrease risk of recurrence while minimizing toxicities and overtreatment. Therefore, it is important to identify patient populations that will benefit most from treatment in order to avoid unnecessary toxicities [3–5]. Patients require different adjuvant therapies based on their risk of recurrence, stage of disease, and tumor biology. In this chapter, we will discuss systemic adjuvant therapy including endocrine therapy, chemotherapy, and HER2-targeted therapy [6, 7]. © Springer International Publishing AG, part of Springer Nature 2013, 2019 |
| Book Title: | Oncoplastic and Reconstructive Breast Surgery. 2nd ed |
| ISBN: | 978-3-319-62925-4 |
| Publisher: | Springer |
| Publication Place: | Cham, Switzerland |
| Date Published: | 2019-01-01 |
| Start Page: | 179 |
| End Page: | 194 |
| Language: | English |
| DOI: | 10.1007/978-3-319-62927-8_13 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter: 13 -- This chapter can be found under "Part I Basic Principles for Oncoplastic and Reconstructive Breast Surgery" -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work